Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens

Metastatic pancreatic cancer is a serious malignancy with limited treatment options and poor outcomes. It is also growing in incidence, and it is projected to be the second leading cause of cancer-related death before 2030. Treatment of pancreatic cancer relies primarily on chemotherapy, though targeted therapies are now available for the approximately 20% of patients who express actionable genetic alterations. Additionally, novel targeted therapies and immunotherapies are showing promise in early phase clinical trials, providing potential future treatment options for this deadly malignancy. Selection between currently available treatment options and ongoing clinical trials relies heavily on biomarkers, as well as performance status, comorbidities, and patient preference. Communicating with patients regarding the importance of biomarker testing, treatment selection, and clinical trials is key to ensuring the best outcomes for patients with metastatic pancreatic cancer.

Share

Program Content

Activities

  • Staying Current with Approved and Emerging Evaluation and Treatment Regimens
    Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 29, 2022

    Expires: July 29, 2023

Faculty

cover img faculity

Michael Pishvaian, MD, PhD

Associate Professor
Department of Oncology
Director
Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
NCR Kimmel Cancer Center
Sibley Memorial Hospital
The Johns Hopkins University School of Medicine
Washington, DC

cover img faculity

Rachna Shroff, MD, MS

Professor of Medicine
Interim Chief, Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, Arizona

Provided by

ProCE Banner
ProCE Banner

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Supporters

This program is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation.

Bayer HealthCare Pharmaceuticals Inc.

Novartis Pharmaceuticals Corporation